Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review

The Lancet Global Health

Volumn 5, Issue 12, 2017, Pages e1208-e1220

  Larney, Sarah ^a   Peacock, Amy ^a   Leung, Janni ^c   Colledge, Samantha ^a   Hickman, Matthew ^d   Vickerman, Peter ^d   Grebely, Jason ^b   Dumchev, Kostyantyn V ^e   Griffiths, Paul ^f   Hines, Lindsey ^g   Cunningham, Evan B ^b   Mattick, Richard P ^a   Lynskey, Michael ^g   Marsden, John ^g   Strang, John ^g   Degenhardt, Louisa ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY   (Ukraine)

^f European Monitoring Center for Drugs and Drug Addiction   (Portugal)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRAL THERAPY; ARTICLE; BIBLIOGRAPHIC DATABASE; CONDOM USE; DATA ANALYSIS; DATA EXTRACTION; DISEASE TRANSMISSION; DRUG USE; HEALTH CARE DELIVERY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; COMPLICATION; DISEASE MANAGEMENT; GLOBAL HEALTH; HIGH RISK BEHAVIOR; PREVENTIVE HEALTH SERVICE; PROCEDURES; REHABILITATION; SUBSTANCE ABUSE; TRANSMISSION; TRENDS;

ANTIRETROVIRUS AGENT;

ANTI-RETROVIRAL AGENTS; DISEASE MANAGEMENT; GLOBAL HEALTH; HEPATITIS C; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85032012733     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(17)30373-X     Document Type: Article

References (34)

1. Degenhardt, L, Peacock, A, Colledge, S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health, 2017 published online Oct 23. http://dx.doi.org/S2214-109X(17)30375-3.
2. Folch, C, Casabona, J, Espelt, A, et al. High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants—is prevention failing?. Subst Use Misuse 51 (2016), 250–260.
3. Paraskevis, D, Nikolopoulos, G, Fotiou, A, et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One, 8, 2013, e78941.
4. Peters, PJ, Pontones, P, Hoover, KW, et al. HIV infection linked to injection use of hydromorphone in Indiana, 2014–2015. N Engl J Med 375 (2016), 229–239.
5. World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, 2012, World Health Organization, Geneva.
6. Degenhardt, L, Mathers, B, Vickerman, P, Rhodes, T, Latkin, C, Hickman, M, Prevention of HIV infection for people who inject drugs: why individual, structural and combination approaches are needed. Lancet 376 (2010), 285–301.
7. Martin, NK, Hickman, M, Hutchinson, S, Goldberg, D, Vickerman, P, Combination interventions to prevent HCV transmission among people who inject drugs: modelling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57:suppl 2 (2013), S39–S45.
8. Turner, KME, Hutchinson, S, Vickerman, P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106 (2011), 1978–1988.
9. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations—2016 update, 2016, World Health Organization, Geneva.
10. Mathers, B, Degenhardt, L, Ali, H, et al. HIV prevention, treatment and care services for people who inject drugs: a systematic review of global, regional and national coverage. Lancet 375 (2010), 1014–1028.
11. UN. A/RES/70/1: Transforming our world: the 2030 Agenda for Sustainable Development. Resolution of the United Nations General Assembly 70th Session of the United Nations General Assembly, September 25, 2015; 2015.
12. WHO. WHO model list of essential medicines. http://www.who.int/medicines/publications/essentialmedicines/en/, 2013 (accessed Oct 6, 2017).
13. WHO. Global health sector strategy on viral hepatitis 2016–2021, 2016, World Health Organization, Geneva.
14. Harm Reduction International. The global state of harm reduction, 2016, Harm Reduction International, London.
15. Alfvén, T, Erkkola, T, Ghys, P, et al. Global AIDS reporting— 2001 to 2015: lessons for monitoring the sustainable development goals. AIDS Behav 21:suppl 1 (2017), 5–14.
16. Cook, C, Bridge, J, McLean, S, Phelan, M, Barrett, D, The funding crisis for harm reduction: Donor retreat, government neglect and the way forward, 2014, Harm Reduction International, London.
17. Bridge, J, Hunter, BM, LAlbers, E, et al. The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model. Int J Drug Policy 27 (2016), 132–137.
18. Open Society Foundations. Undermining the global fight: the disconnect between the Global Fund's strategy and the real-life implications of the new funding model, 2014, Open Society Foundations, New York.
19. Eurasian Harm Reduction Network. The impact of transition from Global Fund support to governmental funding on the sustainability of harm reduction programs: a case study from Bulgaria, 2015, September, 2015, Eurasian Harm Reduction Network, Vilnius, Lithuania.
20. Eurasian Harm Reduction Network. The impact of transition from Global Fund support to governmental funding on the sustainability of harm reduction programs: a case study from Serbia, 2015, Eurasian Harm Reduction Network, Vilnius.
21. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
22. Stevens, G, Alkema, L, Black, R, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet 388 (2016), e19–e23.
23. Larney, S, Degenhardt, L, Peacock, A, Leung, J, Hines, L, Global systematic review on the coverage of HIV prevention and treatment services for people who inject drugs. PROSPERO 2017:CRD42017056558. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017056558, 2017 (accessed Feb 7, 2017).
24. Degenhardt, L, Gibson, G, Leung, J, Kumvaj, M, Larney, S, Searching the grey literature to access research on illicit drug use, HIV and viral hepatitis: a resource to identify drug-related databases and websites. NDARC technical report number 334, 2016, National Drug and Alcohol Research Centre, University of New South Wales, Sydney https://ndarc.med.unsw.edu.au/resource/searching-grey-literature-access-research-illicit-drug-use-hiv-and-viral-hepatitis-resource (accessed May 29, 2017).
25. Mathers, B, Degenhardt, L, Phillips, B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 (2008), 1733–1745.
26. European Centre for Disease Prevention and Control. Thematic report: people who inject drugs, 2015, European Centre for Disease Prevention and Control, Stockholm.
27. East Europe and Central Asia Union of PLWH, Eurasian Harm Reduction Network. Evaluation of program and financial indicators: Russia, 2015.
28. Oprea, C, Ceausu, E, Ruta, S, Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania. Public Health 127 (2013), 1048–1050.
29. Tarján, A, Dudás, M, Wiessing, L, et al. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary—an expanding public health burden. Int J Drug Policy 41 (2017), 1–7.
30. WHO. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance, 2017, World Health Organization, Geneva.
31. Deuba, K, Ojha, B, Shrestha, R, et al. Optimizing the implementation of integrated biological and behavioural surveillance surveys of HIV in resource limited settings—lessons from Nepal. Asian Pac J Trop Dis 4 (2014), S605–S615.
32. Mills, HL, Johnson, S, Hickman, M, Jones, NS, Colijn, C, Errors in reported degrees and respondent driven sampling: implications for bias. Drug Alcohol Depend 142 (2014), 120–126.
33. Rocha, LEC, Thorson, AE, Lambiotte, R, Liljeros, F, Respondent-driven sampling bias induced by community structure and response rates in social networks. J R Statist Soc A 180 (2017), 99–118.
34. Martin, NK, Vickerman, P, Dore, GJ, Hickman, M, The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS 10 (2015), 374–380.